Gamma As Sector portfolio
Concentrated managerType not verifiedPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 12, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Gamma As Sector reported a $461M portfolio of 40 positions to the SEC as of the end of Q2 2026. Its largest positions are BMY, MRK, MDT. During the quarter it opened Thermo Fisher Scientific and Regeneron Pharmaceuticals and exited UnitedHealth Group and Gilead Sciences.
Sections with a free account
What changed this quarter
44 positions with a change (6 new, 19 added to, 11 trimmed, 8 sold). 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Thermo Fisher Scientific+3.7 ppof portfolioNew— → 3.7%
- UnitedHealth Group−2.1 ppof portfolioSold out2.3% → —
- Regeneron Pharmaceuticals+2.1 ppof portfolioNew— → 2.1%
- Biogen−40%fewer sharesReduced3.9% → 2.5%
- Amgen−44%fewer sharesReduced3.9% → 2.1%
- Gilead Sciences−1.6 ppof portfolioSold out1.8% → —
- IQVIA Holdings+94%more sharesIncreased1.6% → 3.3%
- Lantheus Holdings−1.5 ppof portfolioSold out1.7% → —
- Bruker−40%fewer sharesReduced2.2% → 2.0%
- Bristol-myers Squibb−12%fewer sharesReduced11.9% → 9.1%
- Medtronic+26%more sharesIncreased5.7% → 6.0%
- Merck−17%fewer sharesReduced7.4% → 6.0%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Bristol-myers SquibbBMY9.1%
- MerckMRK6.0%
- MedtronicMDT6.0%
- PfizerPFE5.2%
- IncyteINCY4.2%
- Elevance HealthELV3.7%
- BioMarin PharmaceuticalBMRN3.7%
- Thermo Fisher ScientificTMO3.7%
- CVS HealthCVS3.5%
- IQVIA HoldingsIQV3.3%
- Ionis PharmaceuticalsIONS3.3%
- Becton, DickinsonBDX3.1%
- Abbott LaboratoriesABT2.9%
- GE Healthcare TechnologiesGEHC2.9%
- Zimmer Biomet HoldingsZBH2.7%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 40
Q2 2026: 48%
Q2 2026: 19.4%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Type not verified. It meets the portfolio criteria of a concentrated manager, but its type is not verified: we found no official document that is enough to say what kind of entity it is. It may be an investment firm, but also an adviser adding up client accounts, a bank or a family vehicle. It counts in the tallies like the rest; keep that in mind when reading it. How the type is assigned
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- Joho Capital$460M
- United American Securities Inc. (d/b/a UAS Asset Management)Investment firm · $464M
- Kadensa CapitalInvestment firm · $469M
- Winmill$452M
- Progressive Investment Management$452M
- Gardner Lewis Asset ManagementInvestment firm · $449M